78
report
Creating a Nonprofit Marketplace for Shelved Drugs: Lessons from a Pilot Project
Many promising medicines, despite strong safety data and pharmaceutical characteristics, are discon
tinued by drug companies for nonscientific reasons, including strategic, organizational, and financial considerations.
+ Read More
report
Hedging Pipeline Risk in Pharma: FDA Swaps and Annuities
The cost of capital to conduct medical R&D is high because investors must be compensated with s
ignificant returns to offset the risky and long drug-development process.
+ Read More
report
Reducing the Cost and Risk of Dementia
Increased longevity is perhaps one of the greatest success stories of our modern public health syst
em. But along with this success comes one of our greatest challenges to healthy longevity.
+ Read More
report
Nonprofits: A Growing Force in Drug Development
Shepherding a drug from discovery to the market is a complex process that involves many actors.
report
Market Scan: Future of Long-Term Care amid Current Landscape of Barriers and Opportunities
The Milken Institute’s Center for the Future of Aging and Innovative Finance teams are collaboratin
g on a research project to evaluate the most pressing barr,
REFERENCES
+ Read More
report
Beyond the Limits of Traditional Health Care: A State-Level Systematic Review of Community Health Programs in the United States
Traditional health care has not reached all pockets of the U.S. population due to income inequality
, increasing ethnic and cultural diversity, and deep fragmentation of the health care system.
+ Read More
report
Patient-Focused Drug Development Meetings: Smart Practices from Community Leaders
FasterCures, a center of the Milken Institute, designed this guide for patient advocacy organizatio
ns that are interested in hosting, or are currently planning, an externally led patient-focused drug development (PFDD)
+ Read More
report
GBM: Giving Smarter
Glioblastoma Multiforme (GBM) is an aggressive malignant brain tumor involving glial cells of the b
rain. At the time of this report, nearly 15,000 people were diagnosed with GBM each year in the United States and Europe.
+ Read More
report
State Technology and Science Index 2016: Sustaining Americas Innovation Economy
As the Great Recession recedes in our rearview mirrors, it is becoming ever more apparent that inno
vative activities are determining an increasing proportion of the long-term economic growth of cities, metropolitan areas, regions, states, and even natio
+ Read More
report
The Power of Purposeful Aging
This report explains the many physical and cognitive benefits that older people gain when they prov
ide service to others, and the broad social and economic opportunities that derive from their contributions as they age with purpose.
+ Read More
report
Models for Financing Antibiotic Development to Address Antimicrobial Resistance
The Financial Innovations Labs® and FasterCures teams have collaborated on a project to id
report
Demographic Reporting and Mix in Clinical Trials
Clinical trial enrollment can vary based on demographics. Cancer drug trials, for example, have bee
n shown to skew disproportionately toward young, White, male participants.
+ Read More